Search

Search Constraints

You searched for: Author/Creator Butler, Ernest

Search Results

1. 008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. (23rd August 2021)

2. 010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort. (23rd August 2021)

5. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. (October 2018)

6. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Issue 4 (13th January 2019)

7. Confirmed disability progression as a marker of permanent disability in multiple sclerosis. (9th June 2022)

8. Detection of multiple sclerosis lesions in the cervical cord: which of the MAGNIMS 'mandatory' non-gadolinium enhanced sagittal sequences is optimal at 3T?. Issue 6 (December 2021)

9. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. (2nd February 2021)